Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00624234
Other study ID # R01NS049096
Secondary ID NF1-R01R01NS0490
Status Completed
Phase N/A
First received
Last updated
Start date February 2006
Est. completion date January 2017

Study information

Verified date April 2023
Source Vanderbilt University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this trial is to determine if children with neurofibromatosis type 1 who have reading disabilities respond the same way-both behaviorally and neurobiologically-to specialized treatment programs as children with idiopathic reading disabilities do, and to determine which intervention is best for particular learner profiles.


Description:

The most common concern of parents of children with neurofibromatosis type 1 (NF-1) is learning disabilities (LD). Approximately one half of all children with NF-1 have LD-the most debilitating and common of which are reading disabilities. The purpose of this study is to determine if children with NF-1 who have reading disabilities respond the same way-both behaviorally and neurobiologically-to specialized treatment programs known to improve the decoding deficits in children with idiopathic reading disabilities. The trial will also determine which intervention is best for particular learner profiles. The overall purpose of this research is to gain a deeper understanding of the characteristics and treatment of reading disabilities in NF-1. In the trial, researchers will compare children with NF-1 who show weaknesses in reading to children with reading disabilities of no known cause (idiopathic) using two different interventions and behavioral and neurobiological measures. Both interventions focus on teaching sound-symbol relationships, but vary in terms of relative emphasis on verbal versus visual methods of teaching. Scientists hope findings from the trial will advance knowledge about the best therapies for LD in children with NF-1. And, by further refining how children with NF-1 who have reading disabilities are similar (or different) to children with idiopathic reading disabilities, the researchers may be able to learn if reading interventions that address areas other than decoding will also benefit children with NF-1. Also, by understanding the similarities and/or differences in the neuropsychological and neurobiological profiles of children with NF-1 who have reading disabilities, and those without, scientists will be able to refine the cognitive phenotype and neurobiological characteristics of NF-1, which will further understanding of central nervous system abnormalities in NF-1.


Recruitment information / eligibility

Status Completed
Enrollment 184
Est. completion date January 2017
Est. primary completion date March 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria: This study will be open to all individuals, ages 8 to 17 years, who meet eligibility criteria regardless of race, gender, or socioeconomic status. - The Reading Disabilities group (including those with NF-1) is defined by scoring equal to or less than the 25th percentile on measures of basic word reading skills. - The Control group (including those with NF1) is defined by scoring equal to or above the 40th percentile on the average of the Letter Word Identification and Word Attack subtests from the WJ-III. Exclusion Criteria: Any child, regardless of which group he/she is recruited for, will be excluded if he/she meets any of the following criteria (determined during phone screening, medical review, and during testing): - is in foster care; - previous diagnosis of mental retardation; - known uncorrectable visual impairment; - history of known neurological disorder (e.g., epilepsy, spina bifida, cerebral palsy, traumatic brain injury); - documented hearing impairment greater than 25 dB loss in either ear; - medical contraindication to MRI procedures, if participating in MRI (including exposure to metal and pregnancy); - individuals known to have an IQ below 70; - history or presence of a pervasive developmental disorder; - during the DICA-IV parents indicate the presence of any severe psychiatric diagnoses or pervasive developmental disorder.

Study Design


Intervention

Behavioral:
Tutoring Program I
Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
Tutoring Program II
Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.

Locations

Country Name City State
United States Vanderbilt University, Vanderbilt University Institute of Imaging Science Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt University National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in WJ-III Basic Reading Normative Update (Woodcock Johnson Psychoeducational Battery - 3rd Edition; WJ-III NU) Standard Score at 15 Hours This metric measures change in reading abilities, including word recognition and decoding, as assessed by standard educational assessments (Woodcock Johnson Psychoeducational Battery - 3rd Edition Normative Update; WJ-III NU). The scores are reported as change in age-normed standard scores (a change of 15 standard score points would represent a change of 1 standard deviation in the general population).The Basic Reading score is a normed composite of the WJ-III subtests Letter-Word Identification and Word Attack, representing word-level reading skill. 0 and 15 hours
Secondary Neuroimaging Data Neuroimaging data consists of functional MRI and structural MRI measures. Collected before and after intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03190915 - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Phase 2
Completed NCT03326388 - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Phase 1/Phase 2
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Active, not recruiting NCT01362803 - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase 1/Phase 2
Active, not recruiting NCT01218139 - Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients N/A
Recruiting NCT05149469 - Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
Not yet recruiting NCT02505412 - Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients N/A
Terminated NCT02256124 - Effect of Lamotrigine on Cognition in NF1 Phase 2/Phase 3
Completed NCT01707836 - Neurofibromatosis Type 1 Brain Tumor Genetic Risk N/A
Active, not recruiting NCT01218152 - Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs N/A
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Recruiting NCT05186870 - Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
Active, not recruiting NCT03231306 - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Phase 2
Withdrawn NCT03332030 - Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Recruiting NCT02964884 - Interventions for Reading Disabilities in NF1 Phase 2
Recruiting NCT05388370 - PASS of Paediatric Patients Initiating Selumetinib
Recruiting NCT02777775 - Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Completed NCT02944032 - Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 N/A
Completed NCT01851135 - Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 N/A
Completed NCT01410006 - Neurofibromatosis Type 1 Patient Registry N/A

External Links